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Pharmacological blockadea b s t r a c t
Acute mental stress elicits increases in plasma cytokine concentrations in humans, but the underlying
mechanisms remain poorly understood. We assessed the impact of beta-adrenergic blockade on plasma
interleukin 6 (IL-6) and IL-1 receptor antagonist (IL-1Ra) responses in a parallel group, double-blind ran-
domised placebo-controlled trial involving 64 healthy young adult volunteers. Participants were admin-
istered 80 mg slow-release propranolol or placebo daily for 7 days before the stress testing session in
which responses to 3 behavioural challenges (public speaking, mirror tracing, mental arithmetic) were
evaluated. Propranolol administration was associated with reduced baseline levels of heart rate and
IL-1Ra, and systolic blood pressure (BP) in men. Tasks stimulated increased plasma IL-6 concentrations
sampled 45 min and 75 min after challenge, but these responses were blocked by propranolol in men
(p < 0.001). Propranolol did not influence IL-6 responses in women, or IL-1Ra in either sex. Blood pressure
and heart rate increased markedly during the tasks, but there was no differential stress reactivity in pro-
pranolol and placebo conditions. The results of the study support a role of sympathetic nervous system
activation in stimulating acute IL-6 responses to stress, but only in men. The reasons for the differences
between men and women remain to be resolved.
 2018 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Inflammation is involved in a range of serious health problems
including coronary heart disease (CHD), some cancers, chronic
pain, and depression (Elinav et al., 2013; Hansson and
Hermansson, 2011; Louati and Berenbaum, 2015; Miller and
Raison, 2016). Psychosocial factors such as early life trauma, low
socioeconomic status (SES), caregiver strain and other adult stres-
sors have also been associated with low-grade systemic inflamma-
tion (Danese and Lewis, 2017; Kiecolt-Glaser et al., 2015; Rohleder,
2014; Stringhini et al., 2013). This has led to the conjecture that
inflammation mediates in part the association between psychoso-
cial adversity and health outcomes. This link is supported by
experimental studies demonstrating that acute psychological
stress stimulates increased concentration of circulating inflamma-
tory markers, notably interleukin 6 (IL-6) but also IL-1b and tumor
necrosis factor alpha (TNFa) (Marsland et al., 2017; Steptoe et al.,2007). Additionally, individual differences in psychosocial factors
such as loneliness and hostility appear to modulate the magnitude
of inflammatory responses to acute psychological stress (Hackett
et al., 2012; Hackett et al., 2015).
The biological mechanisms underlying inflammatory responses
to acute stress are only partly understood. Psychological stress elic-
its rapid increases in expression of nuclear factor jB (NF- jB), a
transcription factor promoting the production of IL-6 and IL-1b
(Bierhaus et al., 2003; Kuebler et al., 2015). Increases in IL-1b
and IL-6 mRNA expression from leukocytes have also been
described (Brydon et al., 2005; Kuebler et al., 2015; McInnis
et al., 2015). Other factors that may be relevant include redistribu-
tion of circulating white blood cell subpopulations that expression
proinflammatory cytokines, and release of lymphocytes from mar-
ginal pools (Steptoe et al., 2007). Research in animal models
strongly implicates sympathetic nervous system activation in
these responses (Bierhaus et al., 2003; Sanders and Kavelaars,
2007). In humans, positive correlations between plasma IL-6
responses to acute stress and cardiovascular activity have also
been observed, again suggestive of sympathetic nervous system
involvement (Brydon et al., 2005; Kop et al., 2008).
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acute inflammatory responses involves pharmacological blockade
(Van Hedger et al., 2017). Rodent studies indicate that beta-
adrenergic blockade inhibits stress-induced increases in inflamma-
tion (Hanke et al., 2012; Powell et al., 2013), but evidence from
humans is inconclusive. The most detailed study was a double-
blind analysis of 64 healthy middle-aged men and women ran-
domised to daily 80 mg propranolol, 100 mg aspirin or placebo
for 5 days (von Kanel et al., 2008). There was no effect of propra-
nolol on plasma IL-6 responses up to 105 min after the Trier Social
Stress Test (TSST), while aspirin attenuated stress-induced
increases. The explanation for the lack of effect of propranolol is
not clear. Rohleder (2008) suggested that the timing of stress test-
ing might have been relevant, but it is difficult to know what
would have been more appropriate. In an attempt to understand
these processes better, we therefore carried out a parallel group
double-blind trial evaluating the effect of propranolol vs placebo
on IL-6 and cardiovascular responses to acute psychological stress
in healthy young adults. We did not use the TSST but a similar bat-
tery of behavioural challenges, and measured IL-1Ra as an addi-
tional inflammatory biomarker. We hypothesised that 7 days of
80 mg propranolol would block stress-induced increases in inflam-
mation and reduce systolic blood pressure (BP) and heart rate
stress reactivity.2. Method
2.1. Participants
Participants were 69 healthy volunteers recruited from the UCL
campus for a study assessing the effects of pharmacological probes
on stress responsivity. All data were collected with the written
informed consent of the participants and ethical approval was
obtained from the UCL Research Ethics Committee. Participants
were aged 18 years and over, reportedly in good health, and not
taking medications regularly (excluding the contraceptive pill).
Exclusion criteria included haematological, pulmonary, liver, renal,
gastrointestinal, heart, cerebrovascular, and psychiatric disease,
history of thromboembolism, and participants were free of current
infection. Individuals suffering from asthma, who had known aller-
gies to the study medications, previous gastrointestinal bleedings,
or who were currently pregnant or breastfeeding were excluded.
Only those with BP in the normal range were included (90/60 m
mHg–140/90 mmHg). Three people failed to complete the study,
one dropped out because of side effects, and one was excluded
after taking cold medication, leaving 64 in the final sample (20
men, 44 women). Volunteers were paid a small honorarium at
the end of the study. The study was approved by the UCL Research
Ethics Committee, and all participants gave signed informed
consent.2.2. Treatment conditions
Participants were randomised to propranolol or placebo condi-
tions stratified by sex to ensure equal numbers of men and women
in each group. None of the researchers involved in the study were
aware of the treatment condition to which individuals were
assigned. Propranolol is a non-selective beta-blocker, inhibiting
the effects of catecholamines on both b1- and b2-adrenoceptors.
Participants were administered 80 mg of sustained-release propra-
nolol or identical placebo once a day after breakfast for 7 days. The
dose was selected as the minimum recommended clinical dose for
the treatment of hypertension, and was therefore deemed appro-
priate for healthy volunteers in order to minimise the likelihood
of side effects.2.3. Measures and procedure
Participants attended a brief session in the laboratory at which
body composition was measured and a questionnaire containing
demographic and psychosocial measures was completed. They
received a bottle containing 12 pills of the study medication and
were instructed to take one capsule every morning after breakfast
for the following 7 days. Participants were advised not to take any
other medications or herbal remedies while taking part in the
study and to avoid alcohol and vigorous physical activity.
Study participants returned 7 days later for the laboratory
stress session either in the morning (9:00 h) or afternoon (13:30
h), bringing back the pill bottle so that the remaining capsules
could be counted. They were instructed not to exercise before
the session, not to drink alcohol the evening before, and not to con-
sume any caffeine on the morning of the testing day. They were
asked to eat a light breakfast and/or lunch. Anxiety and positive
affect over the past week were assessed. Then a Portapres-2
(Finapres Medical Systems, Amsterdam, NL) was fitted for the con-
tinuous monitoring of BP and heart rate, and an intravenous can-
nula was inserted for blood sample collection. The participant
subsequently rested quietly for 30 min, followed by the baseline
blood draw. Participants also rated subjective stress.
A behavioural task battery consisting of three tasks was then
administered. First was a socially evaluative public speaking task
as previously used by our group (Ghiadoni et al., 2000). The partic-
ipant was asked to imagine a situation in which they had been fal-
sely accused of shoplifting. They were required to prepare a
statement in their defence for 2 min and to present it for 3 min.
They were seated facing a video camera, and were told that images
would be analysed and rated for fluency and competence. Second
was a mirror tracing task used extensively in psychophysiological
research (Matthews et al., 2003; Steptoe et al., 2002). The partici-
pant traced around a star seen in mirror image with a metal stylus
for 5 min. Errors were indicated by a loud sound. The participant
was instructed to trace around the star as many times as possible
in 5 min while making minimal errors. Third was a serial subtrac-
tion task, in which the participant serially subtracted the number
13 from 1,022 as fast and as accurately as possible for 5 min
(Kirschbaum et al., 1993). After every failure, the participant had
to restart at 1,022. Blood pressure and heart rate monitoring con-
tinued throughout, and a second blood sample was drawn immedi-
ately after tasks. Subjective stress was rated after each task, and
participants indicated how difficult they found the task. They then
sat quietly for a further 75 min, with additional blood samples at
45 and 75 min after tasks.
2.4. Measures
Body composition was assessed with a Tanita Body Composi-
tion Monitor (BC-418MA) from which body mass index (BMI)
was derived. Anxiety over the past week was measured with the
7-item anxiety subscale of the Hospital Anxiety and Depression
Scale (HADS) (Zigmond and Snaith, 1983), and positive affect with
the positive affect subscale of the Positive and Negative Affect Scale
(PANAS) (Watson et al., 1988). Scores on the anxiety scale could
range from 0 to 21 and positive affect from 10 to 50, with higher
ratings indicating greater anxiety or positive affect. Subjective
stress and task difficulty were assessed on 7-point scales, with
higher ratings indicating greater stress and perceived task
difficulty.
Blood samples were drawn into EDTA tubes and immediately
centrifuged at 2500 rpm for 10 min at room temperature. Plasma
was removed and aliquoted into 0.5 ml portions and stored at -
80 C until analysis. Plasma IL-6 was analysed with Quantikine
high sensitivity two-site enzyme-linked immunosorbent assay
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tion was between 0.016 and 0.110 pg/ml. IL-1Ra were analysed
in duplicate using fluorescent-labelled capture antibody beads
(Milliplex Human Cytokine/Chemokine kit, Millipore Corporation,
US), and assayed using a Bio-Plex 200 Luminex system (Bio-Rad,
Hemel Hempstead, UK). The limit of detection for IL-1Ra was
2.3 pg/ml. The mean intra-assay coefficient of variations (CVs) for
IL-6 and IL-1Ra were 7.3% and 4.6%, and inter-assay CVs were
7.7% and 6% respectively.2.5. Data reduction and statistical analysis
Systolic and diastolic BP and heart rate were averaged over the
following 5 min periods: 25–30 min of the initial resting period
(baseline), the 5 min of each behavioural task trial, min 15–20,
40–45 and min 70–75 following tasks. Differences in cardiovascu-
lar activity across task trials did not relate to pharmacological
treatment, so the 3 task periods were averaged. Missing data for
individual trials meant that 57 were included in analyses of IL-6
analyses, 59 in analyses of IL-1Ra, and 56 for BP and heart rate. Dif-
ferences between treatment groups in background characteristics
were analysed using analysis of variance with sex and treatment
as between-person factors. Differences in baseline physiology were
explored with analysis of covariance including age, BMI and smok-
ing status as covariates. We analysed subjective stress, inflamma-
tory and cardiovascular responses over the experimental session
with repeated measures analysis of variance with sex and treat-
ment as between-person factors, and trial as the within-person fac-
tor, again adjusting for age, BMI and smoking. Stress responses
were analysed by computing change scores between baseline and
task and recovery trials, including baseline levels as covariates.
The majority of sessions (61.3%) took place in the morning, but
the statistical results were unchanged when time of day was
included as an additional covariate. Significant sex by trial interac-
tions were followed by separate analyses of men and women. Sta-
tistical analyses were performed using SPSS version 24.0 (SPSS Inc.,
Chicago, Illinois, USA).3. Results
Randomization of the 20 men and 44 women in this study
resulted in equally sized propranolol and placebo groups, as
detailed in Table 1. Participants were aged 23.37 years on average,
and had healthy average body weights. The proportion of smokers
was 12.5%, slightly lower than the national prevalence (15.8%).
There were no significant sex or treatment differences in age,
BMI, smoking status, anxiety or positive affect. All participants
reported taking 7 capsules over the treatment period, except one
who took 9 capsules since her stress session had to be rescheduled.
Nine participants (14.8%) reported experiencing side effects that
they attributed to the medication, but this number did not differ
between propranolol and placebo groups (12.9% and 16.7% respec-
tively). Oral contraception was being taken by 12 (27.3%) women,Table 1
Characteristics of study participants Means ± standard deviation or N (percent).
Placebo
Men (n = 9) Women
Age (years) 22.44 ± 3.5 22.13 ± 2
BMI 24.41 ± 2.7 22.73 ± 4
Current smokers 2 (22.2%) 2 (8.7%)
Anxiety 5.44 ± 3.2 5.68 ± 4.
Positive affect 31.44 ± 5.7 35.00 ± 5but was unrelated to the pattern of inflammatory or cardiovascular
responses.3.1. Baseline physiological activity
Physiological activity at baseline is summarized in Table 2. After
adjustment of age, BMI and smoking status, there were no signifi-
cant differences across treatment conditions in baseline IL-6 con-
centration, but levels were higher in women than men (F(1,51) =
7.16, p = 0.010). Baseline concentration of IL-1Ra was lower in
the propranolol than placebo condition (F(1,52) = 6.71, p = 0.012).
There was a main effect of sex in systolic BP (F(1,49) = 4.34,
p = 0.042), together with a sex by treatment interaction
(F(1,49) = 4.95, p = 0.031). The sex by treatment interaction was
significant for diastolic BP as well (F(1,49) = 5.46, p = 0.024). As
can be seen in Table 2, systolic and diastolic BP were lower in
men treated with propranolol compared with placebo, with no
difference in women. The analysis of baseline heart rate showed
a significant main effect of treatment condition (F(1,49) = 11.73,
p < 0.001), with heart rates being substantially lower in the propra-
nolol than placebo groups.3.2. Subjective responses
Stress ratings increased significantly in response to tasks, from a
baseline mean of 1.85 ± 0.96 to 3.80 ± 1.36, 3.82 ± 1.53, and 4.26 ±
1.66 after the speech, mirror tracing, and arithmetic tasks respec-
tively (F(4,228) = 45.61, p < 0.001). There were no differences
between treatment conditions or sexes in these responses. Simi-
larly, ratings of task difficulty (averaging 5.21 ± 1.62 overall) did
not vary between propranolol and placebo conditions (p = 0.32).3.3. Acute inflammatory responses
Analysis of plasma IL-6 concentrations over the session showed
main effects for sex (F(1,50) = 4.67, p = 0.036) and trial (F(3,150) =
36.00, p < 0.001), together with a significant sex by trial interaction
(F(3,150) = 3.92, p = 0.010). Men and women were subsequently
analysed separately. As can be seen in Fig. 1, both men and women
showed significant increases in IL-6 concentration following stress,
with higher levels among women, after adjustment of age, BMI and
smoking status. The treatment by trial interaction was significant
for men but not women (F(3,48) = 8.10, p < 0.001), with a marked
attenuation of IL-6 response to stress in men taking propranolol
compared with placebo. This was confirmed in analyses of differ-
ences in IL-6 concentration at 45 min and 75 min after tasks com-
pared with baseline, with smaller increases at both time points in
the propranolol than placebo group (F(1,12) = 12.00, p = 0.005 and
F(1, 12) = 15.28, p = 0.002 respectively). By contrast, there were no
treatment effects among women.
The analysis of plasma IL1-Ra concentration showed a main
effect of treatment condition (F(1, 51) = 4.55, p = 0.038), but no
sex difference or trial effects. The lower levels of IL1-Ra alreadyPropranolol
(n = 23) Men (11) Women (21)
.9 23.64 ± 2.9 25.00 ± 7.5
.4 22.76 ± 2.5 22.53 ± 2.5
0 (0%) 4 (19.0%)
76 4.70 ± 3.3 4.86 ± 4.62
.9 34.30 ± 3.7 33.67 ± 6.9
Table 2
Baseline biomarker levels Means ± standard deviation adjusted for age, BMI, and smoking status.
Placebo Propranolol
Men Women Men Women
IL-6, pg/ml
N = 57
0.92 ± 0.45 0.91 ± 0.82 0.57 ± 0.19 0.89 ± 0.49
IL-1Ra, log pg/ml
N = 59
6.10 ± 0.56 6.22 ± 0.37 5.80 ± 0.30 6.00 ± 0.33
Systolic BP, mmHg
N = 56
116.2 ± 10.08 105.1 ± 10.30 105.5 ± 8.74 104.9 ± 10.21
Diastolic BP, mmHg
N = 56
71.04 ± 10.74 65.32 ± 8.43 61.30 ± 7.53 64.86 ± 9.06
Heart rate, bpm
N = 56
66.76 ± 7.82 72.08 ± 9.27 60.60 ± 9.45 61.92 ± 5.17
Fig. 1. Mean concentration of plasma IL-6 (in pg/ml) adjusted for age, BMI and
smoking status in samples obtained at baseline, immediately following tasks, and
45 min and 75 min following tasks in men (solid line) and women (dashed line). j
= propranolol d = placebo.
Fig. 2. Mean systolic BP (mmHg, upper panel), and heart rate (bpm, lower panel)
adjusted for age, BMI and smoking, in baseline, task trials, and 15–20 min, 40–45
min, and 70–75 min following tasks in men (solid line) and women (dashed line).j
= propranolol d = placebo.
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mental session, with no significant increases following stress.3.4. Blood pressure and heart rate
Systolic BP responses across the session are shown in Fig. 2
(upper panel) adjusted for age, BMI and smoking status. Both
groups showed marked increases in BP during tasks (F(4,204) =
54.30, p < 0.001), with partial recovery towards baseline over the
post-task period. Systolic BP in men remained somewhat lower
in the propranolol than placebo condition, but there were no sig-
nificant differences in BP responses to tasks related to treatment
in either men or women. A similar pattern was observed for dias-
tolic BP (results not shown).
The analysis of heart rate showed main effects of trial and treat-
ment condition (F(4,204) = 59.49 and F(1,52) = 18.25 respectively,
both p < 0.001). Heart rate increased during tasks and reverted to
baseline levels during the recovery period. The effect of propra-
nolol was more marked in women than men, since there were sig-
nificant treatment effects in all trials (p < 0.001), whereas
differences between treatments were not present in the recovery
period in men.
Associations between IL and 6 and systolic BP responses to
stress were evaluated. Interestingly, systolic BP during tasks was
correlated with IL-6 increases at 45 min (r = 0.80, p = 0.030) and
75 min (r = 0.79, p = 0.035), but only among men in the placebo
condition. There were no associations among men in the propra-
nolol condition, or among women in either treatment group.4. Discussion
This placebo-controlled study evaluated the impact of 7 days
treatment with the beta-blocker propranolol on acute inflamma-
tory responses to mental stress. We hypothesised that propranolol
would attenuate inflammatory and cardiovascular responses. The
results provide only moderate support for this hypothesis. Treat-
ment with propranolol resulted in attenuation of IL-6 responses
to stress, but only in men and not women. Concentration of plasma
IL-1Ra was reduced in the propranolol condition throughout the
experiment, with no differences in stress response. Baseline heart
rate was lower in the propranolol group among both men and
women, while baseline systolic BP was reduced only among men.
However, the intervention did not modify cardiovascular
responses to stress in a clear way. For example, heart rate rose to
a similar extent in response to stress in both placebo and propra-
nolol conditions, although absolute levels were lower in the pro-
pranolol condition.
Mechanistic studies supported by animal research indicate a
prominent role of sympathetic activation in stimulating
expression of inflammatory cytokines in response to acute stress
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1999). Stress-induced expression of norepinephrine could increase
pro-inflammatory cytokines for example by inducing NF- jB tran-
scription. But a previous placebo-controlled study found no effect
of propranolol on plasma IL-6 responses to the TSST in healthy
volunteers (von Kanel et al., 2008). Our study has a similar design,
involving 80 mg slow release propranolol daily, though this was
administered for 7 instead of 5 days. The TSST was not used here,
but the tasks (public speaking, mirror tracing and mental arith-
metic) had similar properties, and were rated as stressful and dif-
ficult. The age of participants in the present study averaged around
25 years younger than those in the experiment conducted by von
Kanel et al. (2008). It is not clear whether these factors accounted
for our observation of an attenuation of IL-6 responses among men
in the propranolol condition. We also showed that propranolol
reduced baseline IL-1Ra, which was not the case for IL-6 suggesting
that beta-adrenergic processes are involved in the production of
IL-1Ra but not of basal IL-6. This result is in line with McNamee
et al (2010) who showed that the beta-adrenoceptor agonist
clenbuterol stimulates IL-1Ra, but not IL-6 in rats.
The reasons for the sex difference in the effects of propranolol
are uncertain. We have no evidence that adherence to medication
was greater in men than women. Estrogen influences the release of
IL-6 (Rachon et al., 2002), but we found no differences in responses
among women related to whether or not they were taking oral
contraception, casting doubt on the relevance of reproductive hor-
mone levels. Significantly larger plasma IL-6 responses to stress
have previously been reported in women than men (Endrighi
et al., 2016; Lockwood et al., 2016), and a similar effect was
observed in this study (Fig. 1). Sex differences in central neuro-
transmitter and corticosteroid responses in relation to stress have
been detailed (Bale and Epperson, 2015; Bekhbat and Neigh, 2018),
but there has been limited focus on sex differences in sympathetic
involvement in inflammatory responses. It is notable in the present
study that plasma IL-6 and systolic BP responses to tasks were cor-
related among men in the placebo condition (an association abol-
ished by propranolol), but not in women; this is consistent with
the notion of sex differences in the role of the sympathetic nervous
system. Evidence for sex differences in adrenergic receptor func-
tion is mixed, with some studies reporting decreased/increased
or no difference on beta-adrenergic receptor responsiveness in
normotensive individuals (Sherwood et al., 2017). Additionally,
there is evidence for greater therapeutic effects of beta-blockers
in men than women (Rosano et al., 2015). Consequently, differ-
ences in beta-adrenergic receptor responsiveness could partly
explain the observed sex differences in our study.
Pharmacological blockade had limited effects on cardiovascular
responses to stress. Although both BP and heart rate were reduced
in the propranolol condition, this was a tonic effect that was
already present at baseline, and stress responses were not affected.
Previous studies have been inconsistent. A single dose of 80 mg
propranolol administered 60 min before the TSST blocked heart
rate responses in one study, but differences in systolic BP were
not significant (Andrews and Pruessner, 2013). Similarly, no signif-
icant effect on BP stress reactions have been observed in other
experiments (Alexander et al., 2007; Dreifus et al., 2014;
Freyschuss et al., 1988). Cardiovascular responses to stress are
highly conserved in many animal species so are likely to be tightly
regulated.
In addition to sympathetic function, other mechanisms not
mediated by noradrenergic receptors that may play a role in
stress-induced inflammation and cardiovascular responses. Gluco-
corticoids play a major role in immune regulation, and are a core
component of the physiological response to stress. Although they
have profound immunosuppressive effects, glucocorticoids may
also enhance inflammation, particularly at low doses (Cain andCidlowski, 2017; Sapolsky et al., 2000). It has been argued that
stress-induced increases in circulating glucocorticoids sensitise
cells to pathogen-associated molecular patterns (PAMPs), danger-
associated molecular patterns (DAMPs) and inflammatory cytoki-
nes (Dhabhar et al., 2012; Del Giudice and Gangestad, 2018). The
parasympathetic nervous system is also implicated, since vagal
stimulation inhibits production of IL-1b and IL-6 (Koopman et al.,
2016). Heart rate variability is reduced during acute stress, with
greater inhibition being associated with larger plasma IL-6
responses (Woody et al., 2017). These mechanisms may serve to
regulate IL-6 responses to stress independently of adrenergic
processes.
Participants’ hedonic state at the time of stress testing was eval-
uated by assessing anxiety and positive affect, while stress percep-
tions were monitored repeatedly across the session. There were no
differences between treatment conditions in either men or women,
although stress ratings did increase as anticipated during beha-
vioural challenges. The purpose of these measures was to ensure
that any differences in physiological responses were not a result
of differences in mood. Likewise, since it is known that task
engagement is associated with larger stress responses (Singer,
1974), we confirmed that task appraisals did not differ between
experimental conditions. Thus differences between propranolol
and placebo could not be attributed to subjective effects.
We did not observe any increase in IL-1Ra concentration follow-
ing stress in this study. The impact of acute stress on IL-1Ra has
been inconsistent (Marsland et al., 2017). Although IL-1Ra shows
a robust association with a number of health risks including cardio-
vascular disease (Herder et al., 2017), its regulation is distinct from
that involved in IL-6 expression (Dinarello, 2009; Schaper & Rose-
John, 2015). One factor that may be relevant is the timing of blood
samples following stress. For example, in one study IL-1Ra
increases peaked at 90 min after stress (Rohleder et al., 2006), while
another only documented responses at 120 min (Steptoe et al.,
2001). The current study measured cytokine levels up to 75 min,
and this may have been too short to demonstrate effects.
This study was carried out with young adults in good health,
and we do not know whether similar findings would emerge with
other groups. Post-menopausal women might not respond in the
same way as the young women tested here because of differences
in hormonal status. We did not use any objective measure of
adherence to medication, but used pill counts, so it is conceivable
that medication was not taken as instructed. The behavioural tasks
generated marked increases in cardiovascular activity, subjective
stress, and plasma IL-6 concentration, but other test protocols
might have different effects. Salivary cortisol samples were col-
lected during the study but proved uninformative, so have not
been presented here. Strengths of the study include a rigorous
double-blind design, detailed evaluation of cardiovascular activity
using a continuous monitoring device, and assessment of subjec-
tive as well as biological responses.
In conclusion, we demonstrated that beta-adrenergic blockade
with propranolol resulted in reductions in plasma IL-6 responses
to acute mental stress, but only in men and not women. Future
studies might measure the impact of beta-blockade on stress-
induced inflammation in clinical samples of individuals with phys-
ical or mental health problems, and assess a broader range of pro
and anti-inflammatory cytokines. The findings support a role of
sympathetic nervous system activation in stimulating acute
inflammatory cytokine responses to stress, but the reasons for
the difference between men and women remain to be resolved.Conflicts of interest
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